Faculty Opinions recommendation of Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.

2006 ◽  
Author(s):  
Nico van Zandwijk
Keyword(s):  
Lung Cancer ◽  
Treatment Group ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Pooled Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
North Central ◽  
Lung Cancer Patients ◽  
The North

Should Elderly Non–Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group

2005 ◽  
Vol 23 (36) ◽  
pp. 9113-9119 ◽  
Author(s):  
Aminah Jatoi ◽  
Shauna Hillman ◽  
Philip Stella ◽  
Erin Green ◽  
Alex Adjei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Pooled Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
The North ◽  
Grade 3

Purpose To answer the question, “should elderly non–small-cell lung cancer patients be offered elderly-specific trials?” Patients and Methods The North Central Cancer Treatment Group (NCCTG) performed a pooled analysis of elderly patients who participated in elderly-specific trials (required age ≥ 65 years) and age-unspecified trials (required age ≥ 18 years). Between 1998 and 2000, all NCCTG non–small-cell lung cancer (NSCLC) patients with incurable cancer, age ≥ 65 years, and receiving first-line chemotherapy were included. A total of 118 elderly patients participated in elderly-specific trials, and 108, in age-unspecified trials. Demographics and outcomes were compared based on trial type. Results The median age of elderly patients in elderly-specific trials was greater: median (range): 73 years (65 to 87) and 70 years (65 to 85), respectively (P < .001), as was the percentage older than 80 years: 17% and 3%, respectively (P = .0008). Median survival times were 232 and 302 days, respectively (P = .08). After adjustment for baseline age, Eastern Cooperative Oncology Group performance score, cancer stage, and body mass index, this survival difference was not statistically significant (hazard ratio = 1.25; P = .16). Grade 3 or worse nonhematologic adverse event rates were greater in age-unspecified trials (81% v 57%, respectively; P < .001), as were grade 3 or worse hematologic events (68% v 10%, respectively; P < .001). Conclusion Elderly patients in NSCLC elderly-specific trials suffered lower rates of severe adverse events with no statistically significant differences in survival. It seems that elderly-specific trials are providing quality care and helping to define optimal cancer therapy in the elderly, particularly among the “oldest of the old.”

scholarly journals Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

2010 ◽  
Vol 14 (1-2) ◽  
pp. 51-69 ◽  
Author(s):  
Luis Paz-Ares ◽  
Denis Soulières ◽  
Ivan Melezínek ◽  
Joachim Moecks ◽  
Lorenz Keil ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Cell Lung Cancer ◽  
Pooled Analysis ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Lung Cancer Patients

The pooled analysis of single gemcitabine for non-small cell lung cancer patients with elderly age

2010 ◽  
Vol 9 (12) ◽  
pp. 683-687
Author(s):  
Fang Wang ◽  
Liangping Xia ◽  
Guifang Guo ◽  
Huijuan Qiu ◽  
Feifei Zhou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Pooled Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Elderly Age ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document